Publicaciones en las que colabora con Eva Pérez Pampín (20)

2019

  1. Evaluation of 12 GWAS-drawn SNPs as biomarkers of rheumatoid arthritis response to TNF inhibitors. A potential SNP association with response to etanercept

    PLoS ONE, Vol. 14, Núm. 2

  2. Specific Association of HLA–DRB1*03 With Anti–Carbamylated Protein Antibodies in Patients With Rheumatoid Arthritis

    Arthritis and Rheumatology, Vol. 71, Núm. 3, pp. 331-339

2018

  1. Validation study of genetic biomarkers of response to TNF inhibitors in rheumatoid arthritis

    PLoS ONE, Vol. 13, Núm. 5

2016

  1. Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis

    Pharmacogenomics Journal, Vol. 16, Núm. 2, pp. 137-140

2015

  1. FCGR polymorphisms in the treatment of rheumatoid arthritis with Fc-containing TNF inhibitors

    Pharmacogenomics, Vol. 16, Núm. 4, pp. 333-345

  2. Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: A case-only study

    Arthritis Research and Therapy, Vol. 17, Núm. 1

2014

  1. Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis

    Pharmacogenetics and Genomics, Vol. 24, Núm. 5, pp. 238-245

  2. Lack of replication of interactions between polymorphisms in rheumatoid arthritis susceptibility: Case-control study

    Arthritis Research and Therapy, Vol. 16, Núm. 1

  3. Lack of validation of genetic variants associated with anti-tumor necrosis factor therapy response in rheumatoid arthritis: A genome-wide association study replication and meta-analysis

    Arthritis Research and Therapy, Vol. 16, Núm. 2

2009

  1. Analysis of TNFAIP3, a feedback inhibitor of nuclear factor-κB and the neighbor intergenic 6q23 region in rheumatoid arthritis susceptibility

    Arthritis Research and Therapy, Vol. 11, Núm. 2

  2. Genetic variation in the nuclear factor κB pathway in relation to susceptibility to rheumatoid arthritis

    Annals of the Rheumatic Diseases, Vol. 68, Núm. 4, pp. 579-583

  3. Lack of association with rheumatoid arthritis of selected polymorphisms in 4 candidate genes: CFH, CD209, Eotaxin-3, and MHC2TA

    Journal of Rheumatology, Vol. 36, Núm. 8, pp. 1590-1595

  4. Rheumatoid arthritis does not share most of the newly identified systemic lupus erythematosus genetic factors

    Arthritis and Rheumatism, Vol. 60, Núm. 9, pp. 2558-2564

2008

  1. Association of interferon regulatory factor 5 haplotypes, similar to that found in systemic lupus erythematosus, in a large subgroup of patients with rheumatoid arthritis

    Arthritis and Rheumatism, Vol. 58, Núm. 5, pp. 1264-1274

  2. Eficacia y seguridad de los tratamientos antagonistas del factor de necrosis tumoral en la artritis reumatoide

    Medicina Clinica, Vol. 130, Núm. 5, pp. 179-187

2007

  1. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists

    Annals of the Rheumatic Diseases, Vol. 66, Núm. 7, pp. 880-885

2006

  1. Actividad asistencial en las consultas externas de las unidades de reumatología de Galicia

    Reumatologia Clinica, Vol. 2, Núm. 5, pp. 239-246

  2. Regulatory polymorphisms in extracellular matrix protease genes and susceptibility to rheumatoid arthritis: a case-control study.

    Arthritis research & therapy, Vol. 8, Núm. 1

  3. SUMO4 and MAP3K7IP2 single nucleotide polymorphisms and susceptibility to rheumatoid arthritis

    Journal of Rheumatology, Vol. 33, Núm. 6, pp. 1048-1051

2004

  1. A CTLA-4 polymorphism associated with susceptibility to systemic lupus erythematosus

    Arthritis and Rheumatism, Vol. 50, Núm. 1, pp. 328-329